Metraipolis › archive › dc_3e00a70add0d

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis — Europe PMC PMID:41853584

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41853584
DOI: 10.1016/j.rpth.2026.103398
License (as archived): solo-consultazione
Archived: 2026-11-05T17:19:05.274Z
SHA-256 of the archived text: 113d0ad372f44f676877e0d659cabfd45019433fd78db1f632294a5a76d04e6f
Stable URL of this page: https://metraipolis.com/documento/dc_3e00a70add0d

How to cite

Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis — Europe PMC PMID:41853584 — Europe PMC (en), https://europepmc.org/article/MED/41853584 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3e00a70add0d (Metraipolis archive dc_3e00a70add0d, sha256 113d0ad372f44f676877e0d659cabfd45019433fd78db1f632294a5a76d04e6f)

BibTeX

@misc{dc3e00a70add0d,
  title = {Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis — Europe PMC PMID:41853584},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41853584},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3e00a70add0d; sha256 113d0ad372f44f676877e0d659cabfd45019433fd78db1f632294a5a76d04e6f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41853584. Agents can read the archived copy with the MCP tool read_document.